Anti‐Malondialdehyde Low‐Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT‐HEART Trial
Anti-MDA-LDL antibody levels were associated with a lower prevalence of aortic and mitral valve calcification. Assessment of these novel biomarkers may be useful in screening patients for valve calcification, as well as providing novel insights into potential pathological relationships.
Authors
- Manuel Mayr (ORCID: https://orcid.org/0000-0002-0597-829X)
- Michelle C. Williams (ORCID: https://orcid.org/0000-0003-3556-2428)
- Adam Hartley (ORCID: https://orcid.org/0000-0003-1431-2200)
- Sarah Verhemel (ORCID: https://orcid.org/0000-0001-9822-7833)
- Damini Dey (ORCID: https://orcid.org/0000-0003-2236-6970)
- Ramzi Khamis (ORCID: https://orcid.org/0000-0003-4119-5193)
- Marc R. Dweck (ORCID: https://orcid.org/0000-0001-9847-5917)
- David E. Newby (ORCID: https://orcid.org/0000-0001-7971-4628)
- Michael Joner (ORCID: https://orcid.org/0000-0002-2971-8310)
- Amit Kaura (ORCID: https://orcid.org/0000-0002-6962-3199)
- Mikhail Caga‐Anan
- Dorian O. Haskard
Institutions
- Cedars-Sinai Medical Center (US)
- British Heart Foundation (GB)
- Imperial College London (GB)
- Technical University of Munich (DE)
- University of Edinburgh (GB)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1161/jaha.125.041524
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00